<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02084238</url>
  </required_header>
  <id_info>
    <org_study_id>2014-03</org_study_id>
    <nct_id>NCT02084238</nct_id>
  </id_info>
  <brief_title>Low-dose IL-2( Interleukin-2) Treatment in SLE</brief_title>
  <official_title>Safety and Efficiency Study of Low-dose IL-2 Treatment in Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Monash University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study will test the efficacy and safety of low dose IL-2 treatment in Systemic
      lupus erythematosus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic lupus erythematosus (SLE) is a chronic autoimmune syndrome affecting various organs.
      While available therapies, such as corticosteroids and immunosuppressive agents have improved
      the outcome of patients, there remains a significant unmet need for safe and more effective
      treatments. Dysfunction of regulatory T (Treg) cells has been detected in diverse autoimmune
      diseases, which can be promoted by interleukin-2 (IL-2). We hypothesized that low-dose IL-2
      could be a novel therapy in active SLE patients.

      This is a single center, uncontrolled, open-label study to assess the efficacy/safety of low
      dose IL-2 plus standard therapy in active SLE.

      Methods: Each SLE patients (n=40) with Scores&gt;=8 on the Safety of Estrogens in Lupus
      Erythematosus National Assessment (AELENA) version of the SLE Disease Activity Index (SLEDAI)
      that was refractory or relaps to glucocorticoid therapy received low-dose IL-2 (1 million
      units every other day subcutaneously (HrIL-2 1X 106, ip, Qod) for a period of 14 days. After
      a 14-day rest, another cycle started) for 3-6 cycles according to the situation of the
      disease. The end points were safety and clinical and immunologic response.

      Expected Results: This trail will define low-dose IL-2 plus standard therapy is efficacy and
      safety with active lupus patients, which could be relevant to the amelioration the abnormity
      of T help cells in SLE patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Were SLE Responders (SRI)</measure>
    <time_frame>week 2，week 4，week 6，week 8，week 10</time_frame>
    <description>SRI response was defined as (1) a ≥ 4-point reduction in SELENA-SLEDAI score, (2) no new BILAG A score or ≤ 1 new BILAG B score, and (3) no deterioration from baseline in the physician's global assessment by ≥ 0.3 points.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunological Responses</measure>
    <time_frame>week 0 and week 10</time_frame>
    <description>Analysis regulatory CD4+ T (Treg) cells , interleukin 17 (IL-17)-producing helper T (Th17) cells and follicular helper T (Tfh) cells before and during IL-2 treatment. P values below 0.05 are considered statistically significant in this study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Immunologic Impact of Low Dose IL-2 Treatment in SLE Patients</measure>
    <time_frame>week 0 and week 10</time_frame>
    <description>Laboratory measures were detected, including, C3, C4 and anti-dsDNA titres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SELENA SLEDAI Score</measure>
    <time_frame>week 0, week 10</time_frame>
    <description>Assessment version of the SLE Disease Activity Index (SELENA-SLEDAI) change. The higher the score represent the worse of the disease. The total score ranges from 0 to 105 points, score&gt; 8 means the disease is moderate-to-severe active&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Relapses</measure>
    <time_frame>24 weeks</time_frame>
    <description>Relapses mean that if the patient's SELENA SLEDAI Score is lower than 4 during the treatment, while the SELENA SLEDAI Score increase after stopping using the study drugs in 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Assessment</measure>
    <time_frame>up to Day 180</time_frame>
    <description>Adverse events includes injection site reactions, influenza-like symptoms, infection, fever, tumor, cardiovascular event，drug-induced liver and kidney damage.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Interleukin-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interleukin-2 to treat activated SLE.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin-2</intervention_name>
    <description>Patients receive low dose recombinant human Interleukin-2（HrIL-2） (1 million units every other day subcutaneously (HrIL-2 1X 106, ip, Qod) for a period of 14 days. After a 14-day rest, another cycle started) for 3-6 courses according to the situation of the disease.</description>
    <arm_group_label>Interleukin-2</arm_group_label>
    <other_name>Recombinant Human Interleukin-2,125Ala, SL Pharm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet the American College of Rheumatology criteria for the diagnosis of SLE.

          -  Under standard treatment (≥ 2 months) at the time of inclusion

          -  Background treatment failed to control flares or to permit prednisone tapering

          -  With at least one of the following manifestations: thrombocytopenia,
             disease-associated rash, mouth ulcer, non-infectious type of fever, active vasculitis,
             renal disorder(proteinuria&gt;0.5g/day), neuropsychiatric SLE.

          -  Positive for at least one of the following laboratory tests: ANA&gt;1:160, anti-dsDNA,
             immunoglobulin&gt;20g/L, decreased C3 or C4, leukopenia&lt;3×10^9/L,
             thrombocytopenia&lt;100×10^9/L;

          -  SLE disease activity index(SLEDAI) ≥ 8.

          -  Negative HIV test.

          -  Negative for hepatitis B and C virus.

          -  Written informed consent form.

        Exclusion Criteria:

          -  Sever chronic liver, kidney, lung or heart dysfunction; (heart failure (≥ grade III
             NYHA), hepatic insufficiency (transaminases&gt; 3N) )

          -  Serious infection such as bacteremia, sepsis;

          -  Cancer or history of cancer cured for less than five years (except in situ carcinoma
             of the cervix or Basocellular carcinoma);

          -  High-dose steroid pulse therapy (&gt;1.5mg/kg) or IV bolus of corticosteroids in the last
             2 months.

          -  History of administration of rituximab or other biologics;

          -  Purified protein derivative (tuberculin) &gt;10mm

          -  Mental disorder or any other chronic illness or drug-abuse that could interfere with
             the ability to comply with the protocol or to give information;

          -  Inability to comply with IL-2 treatment regimen.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhanguo Li, MD and PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Institute of Rheumatology and Immunology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Rheumatology and Immunology, Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2014</study_first_submitted>
  <study_first_submitted_qc>March 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2014</study_first_posted>
  <results_first_submitted>February 20, 2015</results_first_submitted>
  <results_first_submitted_qc>April 10, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 13, 2015</results_first_posted>
  <last_update_submitted>October 2, 2015</last_update_submitted>
  <last_update_submitted_qc>October 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SLE, IL-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between August 2013 and May 2014,38 patients completed three cycles of recombinant human IL-2 (rhIL-2) in Dept. of Rheumatology and Immunology, Peking University People's Hospital. Patients were permitted changes in background therapy according to the treating physician’s advice.</recruitment_details>
      <pre_assignment_details>All the patients showed poor efficacy at least 4 weeks of stable routine treatment at the time of enrollment. Two of the enrolled patients withdrew from the study at week 8: one changed to the belimumab treatment by personal preference; the other elected changed to the cyclophosphamide treatment to reduce the frequency of hospital visits.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Interleukin-2</title>
          <description>Interleukin-2 to treat activated SLE.
Interleukin-2: Patients receive low dose recombinant human Interleukin-2（HrIL-2） (1 million units every other day subcutaneously (HrIL-2 1X 106, ip, Qod) for a period of 14 days. After a 14-day break, another cycle started) for 3-6 courses according to the situation of the disease.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Interleukin-2</title>
          <description>Interleukin-2 to treat activated SLE.
Interleukin-2: Patients receive low dose recombinant human Interleukin-2（HrIL-2） (1 million units every other day subcutaneously (HrIL-2 1X 106, ip, Qod) for a period of 14 days. After a 14-day rest, another cycle started) for 3-6 courses according to the situation of the disease.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31" lower_limit="18" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Forty patients with active SLE were recruited; 38 patients completed three cycles of recombinant human IL-2 (rhIL-2). Two of the enrolled patients withdrew from the study at week 8: one changed to the belimumab treatment by personal preference; the other elected changed to the cyclophosphamide treatment to reduce the frequency of hospital visits.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Study location is in the Dept. of Rheumatology and Immunology, Peking University People’s Hospital.</description>
          <units>partiipants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SELENA-SLEDAI score</title>
          <description>All patients were SLE with moderate-to-severe disease activity (Safety of Estrogens in Lupus Erythematosus National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) &gt; 8.The total score ranges from 0 to 105 points.The higher the points values represent the worse/serious of the disease. Generally, (SELENA-SLEDAI) &gt; 8 means the disease is moderate-to-severe active.</description>
          <units>score</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.35" spread="3.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Were SLE Responders (SRI)</title>
        <description>SRI response was defined as (1) a ≥ 4-point reduction in SELENA-SLEDAI score, (2) no new BILAG A score or ≤ 1 new BILAG B score, and (3) no deterioration from baseline in the physician's global assessment by ≥ 0.3 points.</description>
        <time_frame>week 2，week 4，week 6，week 8，week 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SRI Results</title>
            <description>All 38 patients who completed therapy will be calculated the response rate at each visit time point(week 2,4,6,8,10).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Were SLE Responders (SRI)</title>
          <description>SRI response was defined as (1) a ≥ 4-point reduction in SELENA-SLEDAI score, (2) no new BILAG A score or ≤ 1 new BILAG B score, and (3) no deterioration from baseline in the physician's global assessment by ≥ 0.3 points.</description>
          <units>paticipants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunological Responses</title>
        <description>Analysis regulatory CD4+ T (Treg) cells , interleukin 17 (IL-17)-producing helper T (Th17) cells and follicular helper T (Tfh) cells before and during IL-2 treatment. P values below 0.05 are considered statistically significant in this study.</description>
        <time_frame>week 0 and week 10</time_frame>
        <population>regulatory CD4+ T (Treg) cells , interleukin 17 (IL-17)-producing helper T (Th17) cells and follicular helper T (Tfh) cells</population>
        <group_list>
          <group group_id="O1">
            <title>Immunological Responses 1</title>
            <description>Treg in total CD4+T cells in 23 patients with SLE</description>
          </group>
          <group group_id="O2">
            <title>Immunological Responses 2</title>
            <description>Tfh cells in CD4+ T cells in 23 patients with SLE</description>
          </group>
          <group group_id="O3">
            <title>Immunological Responses 3</title>
            <description>Th17 in CD4+T cells in 23 patients with SLE</description>
          </group>
        </group_list>
        <measure>
          <title>Immunological Responses</title>
          <description>Analysis regulatory CD4+ T (Treg) cells , interleukin 17 (IL-17)-producing helper T (Th17) cells and follicular helper T (Tfh) cells before and during IL-2 treatment. P values below 0.05 are considered statistically significant in this study.</description>
          <population>regulatory CD4+ T (Treg) cells , interleukin 17 (IL-17)-producing helper T (Th17) cells and follicular helper T (Tfh) cells</population>
          <units>Percentage of CD4+ T cells</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" lower_limit="3.54" upper_limit="17.6"/>
                    <measurement group_id="O2" value="3.93" lower_limit="1.27" upper_limit="15.14"/>
                    <measurement group_id="O3" value="4.09" lower_limit="1.69" upper_limit="11.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" lower_limit="4.76" upper_limit="28.2"/>
                    <measurement group_id="O2" value="2.1" lower_limit="0.69" upper_limit="7.55"/>
                    <measurement group_id="O3" value="2.63" lower_limit="1.24" upper_limit="7.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparing the data between baseline and week 10.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Immunologic Impact of Low Dose IL-2 Treatment in SLE Patients</title>
        <description>Laboratory measures were detected, including, C3, C4 and anti-dsDNA titres.</description>
        <time_frame>week 0 and week 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Laboratory Variables 1</title>
            <description>Serum complement 3 in SLE patients</description>
          </group>
          <group group_id="O2">
            <title>Laboratory Variables 2</title>
            <description>Serum complement 4 in SLE patients</description>
          </group>
          <group group_id="O3">
            <title>Laboratory Variables 3</title>
            <description>Serum anti-dsDNA antibodies in patients with SLE</description>
          </group>
        </group_list>
        <measure>
          <title>The Immunologic Impact of Low Dose IL-2 Treatment in SLE Patients</title>
          <description>Laboratory measures were detected, including, C3, C4 and anti-dsDNA titres.</description>
          <units>g/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" lower_limit="0.118" upper_limit="1.46"/>
                    <measurement group_id="O2" value="0.075" lower_limit="0.017" upper_limit="0.54"/>
                    <measurement group_id="O3" value="417.9" lower_limit="10" upper_limit="3987.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" lower_limit="0.45" upper_limit="1.23"/>
                    <measurement group_id="O2" value="0.157" lower_limit="0.11" upper_limit="0.37"/>
                    <measurement group_id="O3" value="105.1" lower_limit="17.14" upper_limit="2467.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SELENA SLEDAI Score</title>
        <description>Assessment version of the SLE Disease Activity Index (SELENA-SLEDAI) change. The higher the score represent the worse of the disease. The total score ranges from 0 to 105 points, score&gt; 8 means the disease is moderate-to-severe active&quot;.</description>
        <time_frame>week 0, week 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SLEDAI Score</title>
            <description>SLEDAI score at week 0 and week 10.</description>
          </group>
        </group_list>
        <measure>
          <title>SELENA SLEDAI Score</title>
          <description>Assessment version of the SLE Disease Activity Index (SELENA-SLEDAI) change. The higher the score represent the worse of the disease. The total score ranges from 0 to 105 points, score&gt; 8 means the disease is moderate-to-severe active&quot;.</description>
          <units>score</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.35" spread="3.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.775" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Relapses</title>
        <description>Relapses mean that if the patient's SELENA SLEDAI Score is lower than 4 during the treatment, while the SELENA SLEDAI Score increase after stopping using the study drugs in 3 months.</description>
        <time_frame>24 weeks</time_frame>
        <posting_date>11/2015</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Assessment</title>
        <description>Adverse events includes injection site reactions, influenza-like symptoms, infection, fever, tumor, cardiovascular event，drug-induced liver and kidney damage.</description>
        <time_frame>up to Day 180</time_frame>
        <posting_date>11/2015</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <desc>No serious adverse events occurred.</desc>
      <group_list>
        <group group_id="E1">
          <title>IL-2 Therapy in SLE</title>
          <description>All enrolled patients completed three cycles of recombinant human IL-2 (rhIL-2). In each cycle, 1 million IU rhIL-2 was administered subcutaneously every other day for 2 weeks, followed by a 2-week break.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection-site reaction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jing He</name_or_title>
      <organization>Peking University People's Hospital</organization>
      <phone>86 ext 1861170734</phone>
      <email>hejing1105@126.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

